Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation
Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifested in an improvement in cognitive status and a decrease in NLC level. Empagliflozin reduces neuronal damage and abnormal microglial activation.
Authors
- Д. А. Суфиева (ORCID: https://orcid.org/0000-0002-0048-2981)
- О. В. Кирик (ORCID: https://orcid.org/0000-0001-6113-3948)
- Т. Д. Власов (ORCID: https://orcid.org/0000-0002-6951-7599)
- О. С. Фукс
- Т. Л. Каронова (ORCID: https://orcid.org/0000-0002-1547-0123)
- Н. В. Тимкина (ORCID: https://orcid.org/0000-0001-9836-5427)
- Д. Э. Коржевский (ORCID: https://orcid.org/0000-0002-2456-8165)
- А. В. Симаненкова (ORCID: https://orcid.org/0000-0003-3300-1280)
Institutions
- First Pavlov State Medical University of St. Petersburg (RU)
- Federal Almazov North-West Medical Research Centre (RU)
- Czech Academy of Sciences, Institute of Experimental Medicine (CZ)
Publication Details
- Journal
- Problems of Endocrinology
- Published
- 2024-09-15
- DOI
- https://doi.org/10.14341/probl13336
- Citations
- 4
- Primary Topic
- Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.99